Oculis (OCS) to Release Earnings on Monday

Key Points

• Oculis is expected to release its Q1 2026 results before the market opens on Monday, May 11, with analysts forecasting ($0.5241) EPS and $0.202M in revenue.
• The company recently missed the prior-quarter EPS (reported ($0.51) vs. consensus ($0.43)) and has very negative margins, while analysts project roughly -$2 EPS for both the current and next fiscal years.
• Shares trade near $27.48 with a market capitalization of about $1.59B, and despite mixed research notes, the consensus rating is a Moderate Buy with a $43.86 target price.

Oculis (NASDAQ:OCS - Get Free Report) will likely be releasing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Oculis to post earnings of ($0.5241) per share and revenue of $0.2020 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 1:00 AM ET.

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.14 million. On average, analysts expect Oculis to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Oculis Price Performance

OCS opened at $27.48 on Monday. The company's 50 day simple moving average is $27.04 and its 200 day simple moving average is $24.01. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.96 and a current ratio of 5.96. Oculis has a 1 year low of $16.00 and a 1 year high of $30.68. The stock has a market capitalization of $1.59 billion, a PE ratio of -12.11 and a beta of 0.38.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new stake in shares of Oculis in the fourth quarter worth $312,000. Marshall Wace LLP purchased a new stake in Oculis during the 2nd quarter worth $393,000. Renaissance Technologies LLC purchased a new stake in Oculis during the 4th quarter worth $499,000. Geode Capital Management LLC increased its holdings in Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company's stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Finally, Bank of America Corp DE increased its holdings in Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company's stock valued at $786,000 after purchasing an additional 878 shares in the last quarter. 22.30% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have weighed in on OCS. Wall Street Zen downgraded shares of Oculis from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Needham & Company LLC boosted their price objective on shares of Oculis from $36.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, March 4th. Stifel Nicolaus upped their price objective on Oculis from $40.00 to $50.00 and gave the stock a "buy" rating in a report on Wednesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $44.00 target price on shares of Oculis in a research report on Monday, April 20th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Oculis in a report on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.86.

Oculis Company Profile

Oculis SA NASDAQ: OCS is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.